New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...
ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy - - ARV-102 was well tolerated across all dose levels following 28 ...
ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear ...
Researchers from IMDEA Materials Institute, in collaboration with China's Nanjing and Huazhong Universities, have developed a ...
FRISCO, CO – March 13, 2026 – PRESSADVANTAGE – Backcountry Chiropractic, a chiropractric practice in Frisco, CO, highlights the qualifications of its founder, Dr. Danny Otis, DC, LCP, DPhCS, who holds ...
EET. Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Dise ...
Recently published Bipolar Depression Market Insights report includes a comprehensive understanding of current treatment practices, ...
The EQT Foundation has launched a new funding call through its Science Grants program aimed at advancing deeptech innovations capable of overcoming the blood-brain barrier, one of the most significant ...
CRF awards four global grants to advance CHM research toward new clinical trial endpoints and therapeutic approaches—driving progress toward treatments.
Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results